Form 4: Catherine Owen Reports Stock Transactions in Agios Pharmaceuticals
SEC Form 4 Filing
Director Catherine Owen reports the vesting of restricted stock units in Agios Pharmaceuticals.
Summary
- Catherine Owen, a director of Agios Pharmaceuticals, reported a transaction involving restricted stock units.
- On June 13, 2024, 1,976 shares of common stock were acquired through the vesting of restricted stock units.
- The restricted stock units were granted on June 13, 2023, and vest in three equal annual installments starting June 13, 2024.
- Following the transaction, Owen directly owns 3,953 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions, with no inherent positive or negative implications.
Future Outlook
Vested shares will be delivered to the reporting person within three business days after such shares become vested.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry.
Stakeholder Impact
- The vesting of stock options and restricted stock units can dilute existing shareholders' equity.
Key Dates
| Date | Description |
|---|---|
| June 13, 2023 | Restricted stock units were granted. |
| June 13, 2024 | Vesting of 1,976 restricted stock units; shares underlying the stock units begin to vest in three equal annual installments. |
| June 17, 2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.